Addex Makes Changes to Executive Management Team
September 18, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 18 September 2017...
Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting
June 23, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Roger Mills elected to the Addex...
Addex Annual General Meeting Scheduled for 22 June 2017
June 06, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland 6 June 2017 -...
Addex Increases Issued Share Capital and Creates Treasury Shares
May 31, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 31 May 2017 -...
Addex ADX71441 Demonstrates Preclinical Analgesic Effects
May 09, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Support Potential of ADX71441 to...
Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology
May 04, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Study Conducted in Collaboration...
Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results
April 05, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 5 April 2017 -...
Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018
February 28, 2017 01:01 ET
|
Addex Therapeutics
Geneva, Switzerland, 28 February 2017 - Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.0 million through a private placement in which 1.5 million treasury...
Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018
February 28, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 28 February 2017...
Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
February 27, 2017 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 27 February...